MOTS-c: A Mitochondrial Signal, Still Awaiting Its Human Trial

The short version

MOTS-c is a very small peptide — just 16 amino acids — made from instructions encoded inside the mitochondrion, the structure inside cells usually described as the cell's power plant. That is unusual: most peptides are built from instructions in the cell's main nuclear DNA. MOTS-c's best-documented action is switching on AMPK, a cellular energy-sensor enzyme that, once active, tends to improve how muscle cells take up and use glucose.

Almost everything known about MOTS-c comes from mice and from cells in a dish. A single human study links naturally circulating MOTS-c levels to lower cardiovascular risk in a small group of dialysis patients ^[2], but that is an observational association, not a trial of the peptide as a treatment. No human efficacy or safety trial of exogenous MOTS-c has been completed. This page describes the published research; it does not recommend a dose, a use, or a source for anyone.

What it is

MOTS-c is encoded by a short open reading frame within MT-RNR1, the mitochondrial gene that also encodes the 12S ribosomal RNA — a stretch of the mitochondrial genome not previously thought to code for a protein. Its sequence, MRWQEMGYIFYPRKLR, is highly conserved across mammalian species, which is usually a sign that a molecule does something biologically important enough that evolution has kept it largely unchanged. MOTS-c belongs to a small class known as mitochondrial-derived peptides (MDPs) — mitochondrial-genome-encoded signaling molecules identified only within the last fifteen years, of which MOTS-c is among the best studied.

How it works

MOTS-c's clearest mechanistic action is inhibiting enzymes in the folate cycle, a metabolic pathway involved in building the molecular building blocks (purines) cells need to divide and function. Blocking part of that cycle raises a molecule called AICAR, which in turn activates AMP-activated protein kinase (AMPK) — a master energy-sensing enzyme that, once switched on, generally pushes cells toward using glucose more efficiently and improves insulin sensitivity, largely in skeletal muscle ^[3].

Under metabolic stress, MOTS-c has also been shown to leave the mitochondrion and travel to the cell nucleus, where it helps regulate the activity of stress-response genes through a partnership with NRF2, a transcription factor central to the body's antioxidant defenses — the first time a mitochondrial-encoded peptide had been shown to signal back to the nucleus this way ^[5]. A 2024 study identified casein kinase 2 (CK2) as a direct molecular binding target, with tissue-specific effects: activating CK2 in muscle while suppressing it in fat, a pattern that helps explain MOTS-c's effects on muscle glucose uptake and its ability to prevent muscle atrophy in the same study ^[1].

What the research shows

Direct molecular target (2024). Working in cell-free systems and in mice — young, aged, on a high-fat diet, and immobilized to induce disuse atrophy — researchers showed MOTS-c directly binds and activates CK2, and that tissue-specific CK2 modulation (activating it in muscle, suppressing it in fat) underlies MOTS-c's prevention of skeletal muscle atrophy and its enhancement of muscle glucose uptake ^[1].

Human cardiovascular association (2024). In a prospective multicenter cohort of 94 chronic hemodialysis patients followed for a median of 26.5 months, circulating MOTS-c was independently associated with a composite endpoint of all-cause mortality and non-fatal cardiovascular events (Cox hazard ratio 1.004, p=0.05), and adding MOTS-c to a risk model modestly improved its discrimination (ROC AUC rising from 0.727 to 0.743) ^[2]. This is among the strongest human data MOTS-c research has produced — and it is an association in existing patients, not a trial of MOTS-c as a treatment.

Exercise and performance (2021). Exercise was shown to induce endogenous MOTS-c expression in skeletal muscle and circulation, and exogenous MOTS-c significantly improved treadmill running capacity (P=0.000002), grip strength, and gait in mice aged 22-23.5 months — old enough to model age-related physical decline — as well as in younger animals ^[4].

Nuclear signaling (2018). Under metabolic stress, MOTS-c was shown to translocate into the nucleus of human and mouse cells and regulate nuclear gene expression, including antioxidant-response genes, in an AMPK-dependent manner ^[5]. A comprehensive 2023 review consolidates this mechanistic picture across the folate-cycle/AMPK axis, nuclear translocation, exercise-inducibility, and roles in metabolic, stress-adaptive, and aging biology ^[3].

Reported effects, cautions & safety

There is no responsible way to summarize community-reported effects for MOTS-c, because — unlike the other two compounds on this guide — the underlying research record contains no verified body of human-use reports to draw from. This page will not invent one.

What can be said, from the published research and its own stated limitations:

• No human efficacy trial exists. Every claim about exogenous MOTS-c improving metabolism, physical performance, or aging comes from mice or cell-based systems; the one human dataset available is an observational biomarker association in existing dialysis patients, not an interventional outcome ^[2].
• No validated human pharmacokinetics. There is no published, measured human half-life, bioavailability, or dose-response relationship. Rodent research doses cannot be reliably converted to a human equivalent.
• Unregulated research-chemical status. MOTS-c is not FDA-approved for any use and is sold only for laboratory research; purity, identity, and sterility are not regulated as they would be for a pharmaceutical.
• Anti-doping prohibition. Anti-doping authorities treat MOTS-c as a prohibited substance in elite sport; athletes who use it risk sanctions.
• A genuine evidence gap. Consumer interest in MOTS-c for fat loss, longevity, and performance considerably outpaces the strength of the underlying evidence — which is exactly the gap this guide exists to make legible.

Where it fits in Metabolic & Weight Research

MOTS-c occupies a different lane from the other two compounds on this guide. Where semaglutide and retatrutide work by activating incretin (and, for retatrutide, glucagon) receptors that gut hormones normally engage, MOTS-c is proposed to act from inside the cell's own energy-management system, via AMPK and mitochondrial-to-nucleus signaling. It earns its place in a metabolic-research field guide on mechanistic grounds — but its evidentiary maturity is the least advanced of the three by a wide margin. See the comparison page for how the three stack up on evidence, regulatory status, and caution.